(Q42793984)

7 November 2017

Diabetes: Breaking news! Rosiglitazone and cardiovascular risk (English)

1 reference

7 November 2017

1 reference

Sanjay Kaul

1

1 reference

PubMed ID

21102630

7 November 2017

George A Diamond

series ordinal

2

1 reference

PubMed ID

21102630

7 November 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Nature Reviews Cardiology

7 November 2017

1 reference

7 November 2017

7

1 reference

7 November 2017

12

1 reference

7 November 2017

670-672

1 reference

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

7 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

Simpson's paradox visualized: the example of the rosiglitazone meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.160

10.1038/NRCARDIO.2010.160

31 March 2020

Identifiers

DOI

1 reference

7 November 2017

1 reference

PubMed ID

21102630